Aquestive Therapeutics
AQST
98 hedge funds and large institutions have $111M invested in Aquestive Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 31 closing their positions.
188% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $661K
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
1% more funds holding
Funds holding: 97 → 98 (+1)
3% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 31
0.61% more ownership
Funds ownership: 46.12% → 46.73% (+0.61%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $177M → $111M (-$66.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.7M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.29M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.68M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$6.58M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$4.26M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$2.99M |
| 4 |
Renaissance Technologies
New York
|
-$2.94M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.83M |
AQST Hedge Fund Activity: Q2 2024 in Review
98 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2024, worth a combined $111M — down 37% from $177M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AQST positions and 31 closed out — a net gain of 1 holder — while 31 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $6.58M sold.
- 98 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2024, up from 97 in Q1 2024.
- Funds reported $111M of Aquestive Therapeutics stock for Q2 2024, down 37% quarter-over-quarter.
- 32 funds opened new Aquestive Therapeutics positions in Q2 2024 and 31 closed out, a net change of +1 holder.
- The largest Aquestive Therapeutics buyer in Q2 2024 was BlackRock, an estimated $13.7M added.
- The largest Aquestive Therapeutics seller in Q2 2024 was Laurion Capital Management, an estimated $6.58M sold.
Based on aggregated 13F filings for Q2 2024.